New drug shows promise for early prostate cancer return

NCT ID NCT06555796

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new drug called xaluritamig in men whose prostate cancer has returned after initial treatment but has not spread. The main goal is to see if the drug is safe and tolerable. About 50 participants will receive the drug, and researchers will monitor side effects and how well the drug controls the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK BIOCHEMICAL RECURRENCE OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK BIOCHEMICAL RECURRENCE OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER HIGH-RISK BIOCHEMICAL RECURRENCE NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Cabrini Hospital

Malvern, Victoria, 3144, Australia
Chris OBrien Lifehouse

Camperdown, New South Wales, 2050, Australia
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
University of Minnesota Medical Center Fairview

Minneapolis, Minnesota, 55455, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.